Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, albeit with a high incidence of hematologic toxicity and infections. The ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...

In this interview, Cerba Research explains how its teams were able to assess clinical response in multiple myeloma (MM) patients that were receiving monoclonal antibodies treatment. In multiple ...

A new T-cell therapy showed benefits in patients with relapsed/refractory multiple myeloma. Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell ...

An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which ...

Please provide your email address to receive an email when new articles are posted on . The two highest doses of REGN5459 conferred a 90.5% objective response rate. Low-affinity binding may lead to ...